How do we assess batch-to-batch consistency between extracellular vesicle products?

Area of Science:

• Biotechnology
• Regenerative Medicine
• Flow Cytometry

Background:

• Extracellular vesicles (EVs) are promising for regenerative and transfusion medicine.
• Mesenchymal stromal cell (MSC)-derived EVs are being developed as cell-free therapeutics under current Good Manufacturing Practice (cGMP).
• A reliable method for ensuring batch-to-batch consistency of cGMP-grade EVs is essential for their therapeutic development.

Observation:

• A multiplex bead-based flow cytometric assay was validated to semiquantitatively assess EV batch-to-batch consistency.
• The assay measures 37 surface markers and includes assay control beads.
• Repeatability, intra-observer reproducibility, and detection limits were rigorously assessed.

Findings:

• The validated assay demonstrated robust repeatability and reproducibility.
• Independently isolated EV batches showed high correlation (Spearman coefficient ≥0.9), indicating statistical indistinguishability.
• Commercially sourced EVs correlated with in-house batches but did not meet the 90% correlation cutoff.

Implications:

• This assay provides a time-efficient and technically simple quality control method for cGMP-grade EV products.
• It enables robust assessment of batch-to-batch reproducibility, critical for therapeutic applications.
• The validated method supports the development and standardization of EV-based cell-free therapeutics.